Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasia

The Department of Leukemia has established the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasia (HAP-CRC-MPN) as a distinct operational unit within the Leukemia Department and Leukemia Outpatient Center. The goal of this clinical research center is to develop a comprehensive approach to understanding the biology of myeloproliferative neoplasms through translational research, leading to new and effective therapies for myeloproliferative disorders.

Under the guidance of Dr. Srdan Verstovsek, Chief of the Section of Myeloproliferative Neoplasms, MD Anderson has become the largest center in the world for MPN patient referral and research. We see annually more than 250 new patients with MPN, far more than any other clinical center in the world, and are engaged continuously in clinical research (conduct of clinical studies) to try to find effective therapies. Nothing of similar proportion exists anywhere in the world.

Components of the HAP-CRC-MPN include:

  • Clinical trials with novel agents developed specifically for patients with MPN
  • Centralized tissue bank and database for collection and annotation of patient samples
  • Education of physicians, patients and their families about the latest in research and treatment of MPNs

Featured Videos

When should MPN treatment begin?

Why Is a Leading MPN Researcher Optimistic About Developing Treatments?

The Social Worker: An Important Part of Your Healthcare Team

Anne’s Story: Why a Clinical Trial Was Right for Me

Lessons from a Care Partner: Living Life to the Fullest

Why do MPNs require a bone marrow biopsy?

Are Clinical Trials Safe? Experts Allay Your Fears

Is MPN a blood cancer or a blood disorder?

How long will MPN treatment last?

Dealing with the Expense of Treatment

Staying active with an MPN: is exercise okay?

What is the significance of blasts in the blood for MPNs?

Finding an MPN specialist, seeking a second opinion